Lacerta Therapeutics
Barb Eppler started their work experience in 2001 as Sr. VP Preclinical and QA at Nanotherapeutics. Barb then moved to Ology Bioservices, Inc. in 2017, where they held the position of SVP Regulatory and Quality. Currently, in 2022, they are working at Lacerta Therapeutics as VP, Quality.
Barb Eppler holds a Ph.D. in Pharmaceutical Sciences from the University of Florida. The dates of their enrollment and graduation from this program are not provided.
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.